Mouse models of endocrine tumours.
Since the onset of the genomic era, there has been tremendous progress in identifying the genetic causes of endocrine tumours. Although this knowledge is valuable in its own right, understanding the molecular basis of tumourigenesis allows the development of new therapies targeted at the causative defects. Understanding the connection between genotype and phenotype is a complex process, which can only be partially understood from the analysis of primary tumours or from the studies of cells in vitro. To bridge this gap, genetically modified mice have been developed to allow molecular dissection of the relevant defects in an intact organism. In this article, we discuss the status of genetic modelling for hereditary and sporadic endocrine tumourigenesis with a goal towards providing a view of how this technology will be of future benefit to clinicians developing specifically targeted therapies for endocrine tumours.
Jones
Georgette N
GN
Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA. Georgette.Jones@osumc.edu
Manchanda
Parmeet K
PK
Pringle
Daphne R
DR
Zhang
Mei
M
Kirschner
Lawrence S
LS
D000818:Animals; D030801:Animals, Genetically Modified; D004195:Disease Models, Animal; D004701:Endocrine Gland Neoplasms / Q000235:genetics* / Q000473:pathology; D006801:Humans; D051379:Mice / Q000235:genetics*